<DOC>
	<DOCNO>NCT02533934</DOCNO>
	<brief_summary>Pilot , open-label study use fix dose combination sofosbuvir /ledipasvir treat HIV/HCV coinfected pre post liver transplant participant</brief_summary>
	<brief_title>Sofosbuvir Ledipasvir HIV/HCV Coinfected Pre Post Liver Transplant</brief_title>
	<detailed_description>Fifty HIV/HCV coinfected liver transplant candidate recipient HCV infection enrol study . Approximately 25 pre-transplant 25 post-transplant patient include . The cohort wait-listed patient cirrhosis due hepatitis C treat SOF/LDV LT maximum 24 week . Patients without HCC within Milan criterion eligible . Another cohort liver transplant recipient recurrent HCV infection post liver transplant also treat SOF/LDV period 12 week ( cirrhosis ) 24 week ( cirrhosis ) . Patients fibrosing cholestatic hepatitis eligible treat 12 week . Starting Day 0 , subject receive SOF/LDV 12 24 week . The total amount time require complete study visit approximately 56 - 68 week screen period end follow-up visit : - Up 8 week Screening period - 12 24 week treatment period - 12 24 week post-treatment follow-up visit ( SVR12 SVR24 ) - 36 week post-treatment ass late viral relapse</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>1 . Over 18 year age screen 2 . A female allow enter participate study either : 1 . Nonchildbearing potential 2 . Childbearing potential , negative urine pregnancy test day 0 prior dosing , agree acceptable birth control 3 . Has receive liver transplant HCV waitlisted liver transplantation due complication HCVcirrhosis ( must approve transplant list internally UNOS ) 4 . Have HIV1 infection either : 1 . On protocol approve HIV medication ( antiretrovirals ) least 4 week WITH HIV viral load less level detection OR 2 . On HIV medication least 8 week WITH CD4 count 500 cells/mm3 OR HIV viral load &lt; 500 copies/mL stable CD4 count least 3 month 5 . Chronic HCV infection document least one measurement plasma HCV RNA ≥ 1,000 IU/mL screen least one following : A positive antiHCV antibody , HCV RNA , HCV genotype test least 12 month prior baseline ( Day 0 ) visit together positive HCV RNA test 6 . HCV genotype 1 , 3 , 4 , 6 7 . Able effectively communicate Investigator center personnel . 8 . Willing give write informed consent comply study restriction requirement . 9 . NIH ONLY : Have primary transplant hepatologist outside NIH medical management . 10 . Willingness allow store blood tissue sample use future study liver disease immune function . 11 . Willingness permit HLA typing perform . 12 . Have transplant team responsible primary transplantrelated care . 1 . Historically documented positive test Screening HBsAg , antiHBc IgM Ab , and/or positive HBV DNA . 2 . History clinically active chronic liver disease ( e.g. , hemochromatosis , autoimmune hepatitis , Wilson 's disease , ≥1antitrypsin deficiency , alcoholic liver disease , toxin exposure ) . 3 . Treatment unlicensed herbal/natural remedy suggest take hepatitis treatment , Milk thistle , St. Johns Wort Cats Claw , within 28 day start treatment 4 . Treatment IFN , RBV , telaprevir boceprevir approve experimental medication know antiHCV activity within 1 month prior screen date 5 . Any prior exposure HCV NS5a specific inhibitor 6 . A personal history first degree relative history Torsade de pointes . 7 . Abnormal hematological biochemical parameter , include : Hemoglobin &lt; 8g/dL ; Estimated GFR , calculate CKDEPI equation , &lt; 30 mL/min/ per 1.73 m2 ; Sodium &lt; 120 mmol/L 8 . History major organ transplantation liver kidney transplantation . 9 . Difficulty blood collection/poor venous access phlebotomy would prevent collection study require sample 10 . Infection require systemic antibiotic time screen 11 . Active recent history ( ≤ 6 month ) drug alcohol abuse 12 . Gastrointestinal disorder postoperative condition could interfere absorption study drug . 13 . Donation loss 400 mL blood within 8 week prior first dose administration . 14 . Any medication prohibit ( see table 2 section 9.2 ) within 28 day prior Day 0 visit likely require study treatment period 15 . History clinically significant drug allergy nucleoside/nucleotide analog . 16 . History current evidence psychiatric illness , endocrine , immunologic disorder , pulmonary , cardiac disease , seizure disorder , cancer condition opinion investigator make patient unsuitable study . Chronic medical condition , especially treated medication ( hypertension ) , must stable time screen . No new therapy start within 28 day prior study may confound assessment study drug safety . 17 . Participation clinical study investigational drug , biologic , device receive within 12 week prior first dose administration . 18 . Pregnant/Breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>HCV Treatment</keyword>
	<keyword>transplant</keyword>
</DOC>